Literature DB >> 18686083

Effect of gelatin on heparin regulation of cytokine release from hyaluronan-based hydrogels.

Robert A Peattie1, Daniel B Pike, Bolan Yu, Shenshen Cai, Xiao Zheng Shu, Glenn D Prestwich, Matthew A Firpo, Robert J Fisher.   

Abstract

The hypothesis that incorporation of small amounts (0.3% w/w) of modified heparin in thiol-modified hyaluronan or HA and gelatin hydrogels would regulate release of cytokine growth factors (GFs) from those gels has been investigated in vitro. In addition, the physiologic response to gel implantation has been evaluated in vivo. Tests were performed with 6 GFs: basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1), keratinocyte growth factor, platelet-derived growth factor-AA (PDGF), and transforming growth factor-beta 1. Release profiles for all 6 over several weeks were well fit by first order exponential kinetics (R(2) > 0.9 for all cases). The most remarkable result of the experiment was a dramatic variation in the total mass ultimately released, which varied from as much as 90.2% of the initial load for bFGF to as little as 1.8% for PDGF, a 45-fold difference. Furthermore, gels containing either VEGF of Ang-1 produced twice the vascularization response in vivo as gels not containing a growth factor. Thus, those GFs maintained strong physiologic effectiveness.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18686083     DOI: 10.1080/10717540802035442

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  12 in total

Review 1.  Hyaluronic acid-based clinical biomaterials derived for cell and molecule delivery in regenerative medicine.

Authors:  Glenn D Prestwich
Journal:  J Control Release       Date:  2011-04-14       Impact factor: 9.776

2.  Molecular weight and concentration of heparin in hyaluronic acid-based matrices modulates growth factor retention kinetics and stem cell fate.

Authors:  Amit K Jha; Anurag Mathur; Felicia L Svedlund; Jianqin Ye; Yerem Yeghiazarians; Kevin E Healy
Journal:  J Control Release       Date:  2015-04-27       Impact factor: 9.776

3.  Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model.

Authors:  Xiaoyu Xu; Glenn D Prestwich
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

4.  VEGF internalization is not required for VEGFR-2 phosphorylation in bioengineered surfaces with covalently linked VEGF.

Authors:  Sean M Anderson; Bhupinder Shergill; Zachary T Barry; Eleana Manousiouthakis; Tom T Chen; Elliot Botvinick; Manu O Platt; M Luisa Iruela-Arispe; Tatiana Segura
Journal:  Integr Biol (Camb)       Date:  2011-08-08       Impact factor: 2.192

5.  Stimulation of in vivo angiogenesis by in situ crosslinked, dual growth factor-loaded, glycosaminoglycan hydrogels.

Authors:  Roberto Elia; Peter W Fuegy; Aaron VanDelden; Matthew A Firpo; Glenn D Prestwich; Robert A Peattie
Journal:  Biomaterials       Date:  2010-03-15       Impact factor: 12.479

Review 6.  Ophthalmic Uses of a Thiol-Modified Hyaluronan-Based Hydrogel.

Authors:  Barbara Wirostko; Brenda K Mann; David L Williams; Glenn D Prestwich
Journal:  Adv Wound Care (New Rochelle)       Date:  2014-11-01       Impact factor: 4.730

Review 7.  Hyaluronic acid hydrogels for biomedical applications.

Authors:  Jason A Burdick; Glenn D Prestwich
Journal:  Adv Mater       Date:  2011-03-10       Impact factor: 30.849

Review 8.  Gelatin carriers for drug and cell delivery in tissue engineering.

Authors:  Marco Santoro; Alexander M Tatara; Antonios G Mikos
Journal:  J Control Release       Date:  2014-04-16       Impact factor: 9.776

9.  Microvascular maturity elicited in tissue treated with cytokine-loaded hyaluronan-based hydrogels.

Authors:  Luke W Hosack; Matthew A Firpo; J Anna Scott; Glenn D Prestwich; Robert A Peattie
Journal:  Biomaterials       Date:  2008-03-03       Impact factor: 12.479

Review 10.  Delivery of EPC embedded in HA-hydrogels for treatment of acute kidney injury.

Authors:  Brian B Ratliff; Michael S Goligorsky
Journal:  Biomatter       Date:  2013-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.